Johnson & Johnson (JNJ) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
Some insider buying ($258K), but sales were much larger ($154M) over the same 12 months.
Past insider buys here: 1 of 1 beat the S&P 500 over the next 90 days (small sample). See each one ↓
Label: Net selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 13, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Elizabeth Forminard, General Counsel sold 13,072 shares at $284.39 ($3.7M).
- Trade date
- Nov 12, 2026
- Disclosed to the SEC
- Nov 13, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All JNJ insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
JNJ insider transactions (Form 4)
Open-market purchases and sales. 115 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 13SEC | Elizabeth ForminardGeneral Counsel | Sell | 13,07216,994 held (−43%) | $284.39 | $3.7M | -6.1% | — |
| Sep 4SEC | Timothy SchmidChair | Sell | 22,52725,447 held (−47%) | $274.74 | $6.2M | -2.8% | — |
| Sep 4SEC | Timothy SchmidChair | Sell | 11,07025,447 held (−30%) | $274.74 | $3.0M | -2.8% | — |
| Aug 18SEC | Jennifer L. TaubertEvp, Wwc. Innovative Medicine | Sell | 15,000194,451 held (−7%) | $263.36 | $4.0M | +1.4% | — |
| Aug 14SEC | Joaquin DuatoCEO, Chair | Sell | 102,315275,967 held (−27%) | $261.00 | $26.7M | +2.3% | — |
| Aug 14SEC | Joaquin DuatoCEO, Chair | Sell | 20,976378,282 held (−5%) | $262.00 | $5.5M | +2.0% | — |
| Aug 7SEC | Joaquin DuatoCEO, Chair | Sell | 41,957282,490 held (−13%) | $258.06 | $10.8M | +3.5% | — |
| Aug 7SEC | Elizabeth ForminardGeneral Counsel | Sell | 9,34423,568 held (−28%) | $257.75 | $2.4M | +3.6% | — |
| Aug 7SEC | Joaquin DuatoCEO, Chair | Sell | 6,523275,967 held (−2%) | $258.74 | $1.7M | +3.2% | — |
| Aug 7SEC | Elizabeth ForminardGeneral Counsel | Sell | 6,57416,994 held (−28%) | $255.93 | $1.7M | +4.4% | — |
| Jul 21SEC | Vanessa BroadhurstEvp, Global Corp Affairs | Sell | 23,05423,003 held (−50%) | $251.27 | $5.8M | +6.3% | — |
| Jun 12SEC | Kathryn E. WengelEvp, Chief To And Risk Officer | Sell | 10,000114,288 held (−8%) | $241.15 | $2.4M | +10.8% | — |
| Mar 3SEC | Robert J. DeckerVp Corporate Controller | Sell | 4,07523,682 held (−15%) | $247.87 | $1.0M | +7.8% | — |
| Feb 23SEC | Timothy SchmidChair | Sell | 1,32225,447 held (−5%) | $245.66 | $325K | +8.7% | — |
| Feb 18SEC | Joseph J. WolkCFO | Sell | 33,38638,961 held (−46%) | $242.75 | $8.1M | +10.0% | — |
| Feb 18SEC | John C. ReedEvp, Innovative Medicine, R&D | Sell | 29,92712,941 held (−70%) | $243.00 | $7.3M | +9.9% | — |
| Feb 18SEC | Joseph J. WolkCFO | Sell | 24,96114,000 held (−64%) | $242.68 | $6.1M | +10.1% | — |
| Feb 18SEC | James D. SwansonEvp, Cio | Sell | 22,19125,020 held (−47%) | $243.71 | $5.4M | +9.6% | — |
| Feb 18SEC | John C. ReedEvp, Innovative Medicine, R&D | Sell | 21,72112,941 held (−63%) | $243.00 | $5.3M | +9.9% | — |
| Feb 18SEC | James D. SwansonEvp, Cio | Sell | 20,52125,698 held (−44%) | $242.70 | $5.0M | +10.1% | — |
| Feb 18SEC | James D. SwansonEvp, Cio | Sell | 19,36825,020 held (−44%) | $243.76 | $4.7M | +9.6% | — |
| Feb 18SEC | Joseph J. WolkCFO | Sell | 19,24138,961 held (−33%) | $242.99 | $4.7M | +9.9% | — |
| Feb 18SEC | Timothy SchmidChair | Sell | 13,62526,769 held (−34%) | $244.20 | $3.3M | +9.4% | — |
| Feb 18SEC | Joseph J. WolkCFO | Sell | 12,06638,961 held (−24%) | $242.87 | $2.9M | +10.0% | — |
| Feb 18SEC | Timothy SchmidChair | Sell | 8,99826,769 held (−25%) | $244.53 | $2.2M | +9.2% | — |
| Feb 18SEC | Vanessa BroadhurstEvp, Global Corp Affairs | Sell | 6,19723,003 held (−21%) | $243.39 | $1.5M | +9.7% | — |
| Feb 18SEC | John C. ReedEvp, Innovative Medicine, R&D | Sell | 2,28310,658 held (−18%) | $243.00 | $555K | +9.9% | — |
| Jan 28SEC | Joaquin DuatoCEO, Chair | Sell | 51,21879,634 held (−39%) | $220.99 | $11.3M | +20.9% | — |
| Jan 28SEC | Joaquin DuatoCEO, Chair | Sell | 48,78230,852 held (−61%) | $221.48 | $10.8M | +20.6% | — |
| Dec 1SEC | John G. MorikisDirectorFirst buyStake +209% | Buy | 1,2501,849 held (+209%) | $206.15 | $258K | +29.6% | — |
| Oct 20SEC | John C. ReedEvp, Innovative Medicine, R&D | Sell | 21,72110,658 held (−67%) | $192.71 | $4.2M | +38.6% | — |
Similar past setups: not applicable. There aren't enough comparable past cases for JNJ's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with JNJ in the Research Lab
Pre-set to JNJ's latest insider buy of $10K or more (Dec 1, 2025: John G. Morikis, $258K). Tap to change anything.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
- After JNJ's buys7, 30 and 90 days later, losses included
- Find buys like this"insiders bought over $250K after a rally in the last 12 months"
- Compare JNJ vs KODInsider buying and selling side by side
- JNJ's board links4 companies share insiders with JNJ
- Play Insider Call5 real buys a day: guess which beat the market
Share price and insider trades
Johnson & Johnson insider trading at a glance (Nov 20, 2026): in the past 12 months, 1 insider bought $258K and 10 sold $154M of JNJ stock on the open market; P/E 43.1 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
JNJ insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $3.7M | 1 |
| Q3 2026 | — | 0 | $67.8M | 10 |
| Q2 2026 | — | 0 | $2.4M | 1 |
| Q1 2026 | — | 0 | $80.5M | 17 |
| Q4 2025 | $258K | 1 | $4.2M | 1 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 1 Johnson & Johnson insider reported open-market purchases totaling $258K, while 10 insiders reported sales totaling $154M. 0 of 30 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
JNJ earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 13, 2026 | -2.8% | None | -3.7%S&P -1.1% | +12.5% |
| Jul 15, 2026 | -1.8% | None | -1.5%S&P -0.1% | +4.2% |
| Apr 14, 2026 | -1.0% | None | +0.3%S&P +2.0% | -5.0% |
| Jan 21, 2026 | +6.8% | None | +0.1%S&P +1.7% | +11.0% |
| Oct 14, 2025 | +6.2% | None | +0.1%S&P +0.3% | +2.5% |
| Jul 16, 2025 | +1.6% | None | +5.0%S&P +0.9% | +8.4% |
| Apr 15, 2025 | -5.7% | None | -0.3%S&P -2.5% | -1.7% |
| Jan 22, 2025 | +3.1% | None | -1.0%S&P +1.1% | +11.6% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
JNJ short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded JNJ
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| John BoozmanSenate | Sold $1,001 - $15,000 | Aug 20, 2026 | Sep 11, 2026 | +0.4% |
| Thomas H TubervilleSenate | Sold $15,001 - $50,000 | Oct 29, 2024 | Aug 5, 2026 | +76.1% |
| Thomas H TubervilleSenate | Sold $15,001 - $50,000 | Oct 29, 2024 | Aug 5, 2026 | +76.1% |
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 30, 2026 | Jul 21, 2026 | +11.3% |
| Alan ArmstrongSenate | Bought $15,001 - $50,000 | Mar 27, 2026 | Jul 21, 2026 | +12.3% |
| John BoozmanSenate | Sold $1,001 - $15,000 | Mar 19, 2026 | Apr 14, 2026 | +13.6% |
What happened after JNJ insiders bought
Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.
| Filed | Insider | Bought | 7 days | 30 days | 90 days |
|---|---|---|---|---|---|
| Dec 1, 2025 | John G. MorikisDirector | $258K | -1.8%-2.3% vs S&P | +0.8%+0.2% vs S&P | +21.7%+20.5% vs S&P |
Insiders at Johnson & Johnson
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Joaquin DuatoCEO, Chair | — | $66.8M | Aug 14, 2026 | — | — |
| Joseph J. WolkCFO | — | $21.8M | Feb 18, 2026 | — | — |
| John C. ReedEvp, Innovative Medicine, R&D | — | $17.3M | May 4, 2026 | — | — |
| James D. SwansonEvp, Cio | — | $15.1M | Feb 18, 2026 | — | — |
| Timothy SchmidChair | — | $15.1M | Sep 4, 2026 | — | — |
| Elizabeth ForminardGeneral Counsel | — | $7.8M | Nov 13, 2026 | — | — |
| Vanessa BroadhurstEvp, Global Corp Affairs | — | $7.3M | Jul 21, 2026 | — | — |
| Jennifer L. TaubertEvp, Wwc. Innovative Medicine | — | $4.0M | Aug 18, 2026 | — | — |
| Kathryn E. WengelEvp, Chief To And Risk Officer | — | $2.4M | Jun 12, 2026 | — | — |
| Robert J. DeckerVp Corporate Controller | — | $1.0M | Mar 3, 2026 | — | — |
| John G. MorikisDirector | $258K | — | Dec 1, 2025 | — | — |
| Kristen MulhollandEvp, Chief Hr Officer | — | — | Feb 18, 2026 | — | — |
Board links: companies that share insiders with JNJ
Directors and executives who filed Form 4s for JNJ and another company in the last 12 months.
- GISGeneral Mills John G. Morikis Director here · Director at GIS · latest filing Oct 1, 2026
- LHLabcorp Kathryn E. Wengel Evp, Chief To And Risk Officer here · Director at LH · latest filing Jun 12, 2026
- PRUPrudential Financial Joseph J. Wolk CFO here · Director at PRU · latest filing Feb 18, 2026
- ZTSZoetis Vanessa Broadhurst Evp, Global Corp Affairs here · Director at ZTS · latest filing Jul 21, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
JNJ stock: common questions
Are Johnson & Johnson insiders buying JNJ stock?
In the past 12 months, 1 insider reported open-market purchases of JNJ worth $258K. The latest was Director John G Morikis bought $258K of JNJ at $206.15 — first open-market purchase in our records; raises the stake by 209%.
Are Johnson & Johnson insiders selling JNJ stock?
10 insiders reported sales worth $154M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is JNJ's P/E ratio?
JNJ trades at about 43.1 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is JNJ's 52-week range?
Over the past year JNJ has traded between $196.79 and $285.75. It last closed at $267.11 on Nov 19, 2026.